Genetic differences in estrous cycle effects on the rat brain transcriptome
Ontology highlight
ABSTRACT:
ORGANISM(S): Rattus norvegicus
PROVIDER: GSE159009 | GEO | 2020/10/06
REPOSITORIES: GEO
Similar Datasets
Project description:DNA damage can promote altered RNA splicing and decreased gene expression (Gregersen and Svejstrup, 2018; Milek et al., 2017; Munoz et al., 2009; Shkreta and Chabot, 2015), and aberrant splicing is implicated in neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), Fragile X syndrome and spinal muscular atrophy (SMA) (Conlon et al., 2016; Jia et al., 2012; Loomis et al., 2014; Qiu et al., 2014; Scotti and Swanson, 2016). Therefore, we used RNA-seq data to assess RNA-splicing in double-mutant brain tissue using multivariate analysis of transcriptional splicing (rMATS) (Shen et al., 2014) and a splicing deficiency score algorithm (Bai et al., 2013) to assess intron retention.
2021-12-14 | GSE174841 | GEO
Project description:MV130 is an inactivated polybacterial mucosal vaccine that confers protection to patients against recurrent respiratory infections, including those of viral etiology. We showed that MV130 induces long term heterologous protection against viral respiratory infections in mice. Moreover, intranasal administration of MV130 provided protection against systemic candidiasis in wild-type and Rag1-deficient mice lacking functional lymphocytes, indicative of innate immune-mediated protection. As trained immunity acts via modulation of hematopoietic stem and progenitor cells (Kaufmann et al., 2018; Mitroulis et al., 2018) we hypothesized that MV130 could confer systemic long-term protection through reprogramming of hematopoietic precursors. For that we measured the chromatin accessibility landscape in multipotent progenitors (MPPs) coming from mice treated with MV130 or its excipient using ATAC-seq.
2021-11-10 | GSE183486 | GEO
Project description:Lewy body (LB) pathology and loss of dopaminergic neurons are imprints of Parkinson’s disease (PD). LBs are mainly comprised of alpha-Synuclein (Dijkstra et al., 2014). Strolling detection of LBs in brain regions contribute to progressive construct of PD pathology to which molecular mechanisms are not clear (H. Braak & Del Tredici, 2017). Two key facets of LB formation are protein aggregation via misfolding and transmission of misfoldled proteins to various brain regions, eventually causing neuronal death (Goedert, Spillantini, Del Tredici, & Braak, 2013; Pacelli et al., 2015). Misfolding requires alterations in intracellular physiology (Carbone, Costa, Provensi, Mannaioni, & Masi, 2017; Funes et al., 2014; Guzman et al., 2018; Pacelli et al., 2015) and detection of misfolded proteins in exosomes confirms exosomatic transmission (Ngolab et al., 2017). High levels of neurotropic-factors (Brockmann et al., 2017) and changes in bioenergetics are found in PD patients, these can bring physiological alterations (Smith et al., 2018). En masse, these evidences and hipocampal association with synucleopathies (Flores-Cuadrado, Ubeda-Bañon, Saiz-Sanchez, de la Rosa-Prieto, & Martinez-Marcos, 2016) allowed us to probe other volunerable PD proteins in cell-lysate and exosomal proteomes of bFGF treated hippocampal neurons. Using WPCNA we developed co-expression modules and spotted many PD related proteins; which can act as precursors during diseased or onset stage.
2020-07-21 | PXD015969 | Pride
Project description:Growth differentiation factor 11 (GDF11), also known as bone morphogenetic protein 11 (BMP11) is a member of the Growth differentiation factors (GDFs), a subfamily of proteins belonging to the transforming growth factor-beta (TGF-β) superfamily (Katoh and Katoh 2006). ). In the past 7-8 years, several high profile studies, showed that systemic restoration of GDF11 levels reverses age-related phenotypes and rejuvenated heart and skeletal muscle in aged mice (Loffredo, Steinhauser et al. 2013, Sinha, Jang et al. 2014), improves insulin sensitivity via restoring pancreatic β-cell function in diabetic mice (Li, Li et al. 2017), and increases proliferation of brain capillary endothelial cells thereby improving the vascular and neurogenic rejuvenation in the brain of aged mice (Katsimpardi, Litterman et al. 2014, Finkenzeller, Stark et al. 2015, Zhang, Guo et al. 2018). Nonetheless, the possible rejuvenation effect of GDF11 was questioned over past years by several other studies. These reports doubted the age-associated decrease of circulating GDF11 level and related phenotypes in the muscle, the heart and the brain (Egerman, Cadena et al. 2015, Rodgers and Eldridge 2015); moreover, restoration of GDF11 levels in old mice had no positive effect on heart structure or function (Smith, Zhang et al. 2015). Increase of GDF11 levels had deleterious effects on aging skeletal muscle regeneration (Egerman, Cadena et al. 2015), suggesting also that supraphysiological levels could lead to cachexia (Hammers, Merscham-Banda et al. 2017). In the field of liver diseases, GDF11 was shown to exhibit tumor suppressive properties in HCC cells (Zhang, Pan et al. 2018, Gerardo-Ramírez, Lazzarini-Lechuga et al. 2019) and to worsen hepatocellular injury and liver regeneration after liver ischemia reperfusion injury (Liu, Dong et al. 2018). From these controverted studies, it is clear that the systemic effects of GDF11 in health and disease are not yet clearly and fully delineated. The aim of the present study was to specifically characterize the role of GDF11 in lipid metabolism and in the progression of the NAFLD disease spectrum, which is currently unknown. We thus aimed at investigating the potential effect of GDF11 on lipid droplet formation in human hepatocytes. Our data strongly suggest that GDF11 supplementation exacerbates, both in presence or absence of FFA, lipid droplet accumulation in two hepatic cell models (HepG2 and Hep3B) by impinging on ALK5/SMAD2/3 dependent signaling pathway.
2019-08-14 | GSE135796 | GEO
Project description:VSMCs expressing SCA1 have increased proliferative capacity (Dobnikar et al, 2018; Worssam et al, 2022; Pan et al, 2020). We therefore, mapped chromatin accessibility changes using bulk ATAC-seq for SCA1+ and SCA1- lineage traced VSMCs.
2024-04-09 | GSE246646 | GEO
Project description:ChIP-seq data (H3K4Me3, H3K27Ac histone modifications) of Hodgkin lymphoma cell line L-428. Samples were processed as previously described (Sud et al., 2018). The files are in bam format, aligned to build 37.
| EGAS00001003033 | EGA
Project description:The neural behavior of glioblastoma, including the formation of tumor microtubes and synaptic circuitry, is increasingly understood to be pivotal for disease manifestation (Osswald et al. 2015; Venkatesh et al. 2015; Weil et al. 2017; Venkataramani et al. 2019; Venkatesh et al. 2019; Alcantara Llaguno et al. 2019; Venkataramani et al. 2022). Nonetheless, the few approved treatments for glioblastoma target its oncological nature, while its neural vulnerabilities remain incompletely mapped and clinically unexploited. Here, we systematically survey the neural molecular dependencies and cellular heterogeneity across 27 glioblastoma patients and diverse model systems. In patient tumor samples taken directly after surgery, we identify a spectrum of neural stem cell morphologies indicative of poor prognosis, and discover a set of repurposable neuroactive drugs with unexpected and consistent anti-glioma efficacy. Glioblastoma cells exhibit functional dependencies on highly expressed drug targets including neurological ion channels and receptors, while interpretable molecular machine learning reveals downstream convergence on secondary drug targets (COSTAR) involving AP-1-driven tumor suppression. COSTAR enables in silico drug screening on >1 million compounds that are validated with high accuracy. Multi-omic profiling of drug-treated glioblastoma cells confirms rapid Ca2+-driven AP-1 pathway induction to represent a tumor-intrinsic vulnerability at the intersection of oncogenesis and neural activity-dependent signaling. Finally, the consistent anti-glioma activity across patients and model systems is epitomized by the antidepressant Vortioxetine, which synergizes in vivo with approved glioblastoma chemotherapies. In all, our global analysis reveals that the neural vulnerabilities of glioblastoma converge on an AP-1 mediated gene regulatory network with direct translatable potential.
2024-08-01 | PXD037015 | panorama
Project description:ChIP-seq data (H3K4Me3, H3K27Ac histone modifications) of Hodgkin lymphoma cell line L-428. Samples were processed as previously described (Sud et al., 2018). The files are in bam format, aligned to build 37 of the human genome.
| EGAD00001004322 | EGA
Project description:Down syndrome (DS) is a neurodevelopmental disorder caused by an extra copy of human chromosome 21 (HSA21). People with Down syndrome have poor motor skills and speech, impaired adaptive behavior, and cognition deficits. (Carlesimo et al., 1997; Contestabile et al., 2010; Roizen and Patterson, 2003; Sherman et al., 2007; Vicari et al., 2000). At the brain anatomical level, DS is characterized by structural deficiencies in diverse regions. These deficits include hippocampal and cortical growth reduction, abnormal lamination and differentiation of neurons, decreased dendritic branching and spine density, and abnormal synaptic plasticity (Kazemi et al., 2016; Rachidi and Lopes, 2011). Even though the genetic cause of DS was discovered in 1959 (Megarbane et al., 2009), we still do not know the precise mechanisms by which triplication of HSA21 genes leads to neuroanatomical and neurobehavioral phenotypes in DS individuals. Moreover, a fundamental question in DS is to discover the impact of the triplication of chromosome 21 on the global expression regulation of non-triplicated genes (Letourneau et al., 2014) and how these profound changes at the genetic level translate to phenotypic changes in DS individuals. Finally, drug treatments targeting various putative molecular pathways are effective in rescuing cognition in DS animals. Nevertheless, while the preclinical studies performed in diverse mouse models of DS have reported improvement in cognitive deficits, the same drugs have failed to replicate all the good and promising effects when administered to people with DS during clinical trials (Rueda et al., 2020). Therefore, there is a notable need in strongly extending our understanding of DS in humans. Global gene expression analysis at the mRNA or protein level with different techniques have reported interesting findings on disparate DS-derived samples (fibroblasts, circulating immune cells, and amniocytes) (Guedj et al., 2016; Stamoulis et al., 2019; Waugh et al., 2019; Lanzillotta et al., 2020; Liu et al., 2017. Liu et al., 2018; Sommer et al., 2008) or iPSC-derived neurons obtained from DS individuals (Gonzales et al., 2018; Huo et al., 2018; Sobel et al., 2019). However, only a few studies have directly assessed global mRNA dysregulation in the adult DS brains by microarray hybridization (Lockstone et al., 2007; Olmos-Serrano et al., 2016). Although the latter studies have provided interesting information about the significant cellular pathways altered in trisomy, they lacked the depth, sensitivity, and isoform specificity that characterize modern gene expression analysis by next-generation sequencing (NGS). In this regard, another study used single-nucleus RNA sequencing (snRNA-seq) to profile aging DS brains (Palmer et al., 2021). Although this cutting-edge technique can deliver high-level information for the characterization of cellular diversity in brain tissues, this comes at the cost of profiling less number of genes (Bakken et al., 2018) and the possibility of missing the specific signature of important pathological processes (Thrupp et al., 2020). Moreover, none of these studies addressed the other side of the coin, assessing the corresponding changes in protein expression. In fact, the question of how well the transcriptome expression profiles match with those at the protein level remains largely unanswered. Large-scale analysis of transcriptome and proteome of the human brain would therefore provide a more comprehensive data-driven approach to identify dysregulated biological processes or genes/proteins co-expression networks as drivers of disease pathogenesis and prioritize the development of corresponding therapeutic interventions. Here, we took a multi-level data acquisition and interpretation approach to integrate in-depth transcriptomics and proteomics data in parallel from the same set of human brain samples to identify dysregulated expression networks in DS, a complex and multigenic neurodevelopmental disorder. We also provide unprecedented evidence of changes in mRNA transcript (isoform) expression, and to our knowledge, a first integrative analysis to identify alternative splicing, RNA binding proteins, and miRNAs as crucial intermediate regulatory steps in DS. Our data provide molecular information signatures that consistently repeat at gene, transcript, and protein levels and may function as critical players in DS pathophysiology. In particular, our multi-level data pinpoint to alteration in cell projection genes that translate into defects in axon and dendrites formation, which we find in DS iPSC derived neurons and primary hippocampal culture from a murine DS model.
2024-06-03 | PXD038791 | Pride
Project description:In this study, we profiled for LINE1 binding loci in RSeT+DT naïve hES cells with the Chromatin Isolation by RNA Purification (ChIRP)-seq strategy. We followed a previously published ChIRP protocol described (Percharde et al. 2018; Lu et al. 2020).
2024-09-09 | GSE263289 | GEO